Effects of SGLT2 inhibitors on cardiovascular outcomes (Q37989674)

26 August 2017

Effects of SGLT2 inhibitors on cardiovascular outcomes (English)

1 reference

26 August 2017

1 reference

3

1 reference

26 August 2017

Vlado Perkovic

2

0 references

author name string

Celine Foote

series ordinal

1

1 reference

PubMed ID

22381403

26 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

Diabetes and Vascular Disease Research

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

117-123

1 reference

26 August 2017

2

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

26 August 2017

1 reference

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Dualities of interest are not restricted to financial ties to the pharmaceutical industry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Rosiglitazone: what went wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Current therapies and emerging targets for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response t

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164112441190

21 January 2018

Identifiers

DOI

10.1177/1479164112441190

1 reference

26 August 2017

1 reference

PubMed ID

22381403